Clinical Trial

Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Participants With B-cell Malignancies

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the long-term safety of zanubrutinib regimens in participants with B-cell malignancies who participated in a BeiGene parent study for zanubrutinib.
Protocol Amendment History 24 amendments
This ClinicalTrials.gov record has been amended 24 times since 2019-11-19; most recent amendment 2025-10-20.
Status change: Enrolling by Invitation → Active, Not Recruiting 2025-09-30
Status change: Recruiting → Enrolling by Invitation 2024-07-22
Status change: Enrolling by Invitation → Recruiting 2024-04-24
Status change: Recruiting → Enrolling by Invitation 2020-04-23
Status change: Not Yet Recruiting → Recruiting 2020-01-29
Trial Details
NCT Number NCT04170283
Lead Sponsor BeiGene
Conditions B-cell Malignancies
Enrollment 955 participants
Start Date 2020-01-16
Primary Completion 2027-11 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2025-10-21